Giant Biogene Holding Co., Ltd. (HKG:2367)

Giant Biogene Holding Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6,306	4,030	2,504	1,331	7,103
Short-Term Investments	38.08	19.5	11.03	21.31	4.88
Trading Asset Securities	1,984	1,829	1,275	865.97	155.61
Cash & Short-Term Investments	8,329	5,878	3,790	2,218	7,263
Cash Growth	41.68%	55.11%	70.85%	-69.46%	270.86%
Accounts Receivable	201.87	141.28	102.03	69.42	65.64
Other Receivables	27.06	7.34	14.55	4.6	6.7
Receivables	228.92	148.62	116.57	74.02	72.34
Inventory	391.07	310.81	200.44	183.9	89.39
Other Current Assets	69.99	64.17	28.26	61.58	16.11
Total Current Assets	9,019	6,402	4,135	2,538	7,441
Property, Plant & Equipment	1,257	1,093	711.62	551.65	333.53
Long-Term Investments	420.53	451.84	-	-	-
Other Intangible Assets	4.98	5.82	7.36	6.75	7.6
Long-Term Deferred Tax Assets	0.52	0.91	1.11	1.19	1.35
Other Long-Term Assets	140.12	84.65	117.91	40.9	94.41
Total Assets	10,841	8,038	4,973	3,138	7,878

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	198.57	286.71	133.11	54.65	23.61
Accrued Expenses	73.36	61.36	40.72	28.5	28.93
Current Portion of Leases	6.43	4.7	1.56	0.88	-
Current Income Taxes Payable	70.35	117.02	116.72	75.02	71.36
Current Unearned Revenue	19.38	18.68	37.25	13.95	17.78
Other Current Liabilities	431.89	347.53	201.25	107.9	6,701
Total Current Liabilities	799.96	836	530.61	280.91	6,843
Long-Term Leases	3.26	2.01	1.17	1.71	-
Long-Term Unearned Revenue	16.32	18.93	19.58	18.18	17.58
Long-Term Deferred Tax Liabilities	97.09	61.2	50.68	0.4	0.77
Total Liabilities	916.64	918.14	602.03	301.19	6,861

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.07	0.07	0.06	0.06	0.06
Additional Paid-In Capital	5,146	2,736	1,695	1,597	7,160
Retained Earnings	4,864	4,229	2,619	1,167	164.8
Treasury Stock	-166.15	-0	-0	-0	-0
Comprehensive Income & Other	67.1	143.53	48.81	69.72	-6,308
Total Common Equity	9,911	7,108	4,362	2,833	1,017
Minority Interest	13.31	11.61	8.91	3.56	-
Shareholders' Equity	9,925	7,120	4,371	2,837	1,017
Total Liabilities & Equity	10,841	8,038	4,973	3,138	7,878

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	9.69	6.71	2.73	2.59	-
Net Cash (Debt)	8,319	5,872	3,787	2,216	7,263
Net Cash Growth	41.68%	55.04%	70.92%	-69.50%	270.86%
Net Cash Per Share	7.85	5.86	3.85	2.17	7.26
Filing Date Shares Outstanding	1,066	1,016	976	976	900
Total Common Shares Outstanding	1,066	1,016	976	976	900
Working Capital	8,219	5,566	3,604	2,257	598.28
Book Value Per Share	9.30	7.00	4.47	2.90	1.13
Tangible Book Value	9,906	7,102	4,355	2,827	1,009
Tangible Book Value Per Share	9.30	6.99	4.46	2.90	1.12
Buildings	590.42	580.02	285.49	225.79	184.61
Machinery	345.17	214.6	131.75	104.62	69.28
Construction In Progress	459.18	387.88	356.25	244.44	81.58
Leasehold Improvements	44.31	21.69	9.54	5.56	1.86

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 1, 2026

Data Sources Report a data error